Help Simmaron Fund the Rise of ME/CFS Research!

Author:

Simmaron Powers Change in 2015!
2015 marks a powerful turning point for ME/CFS patients, and it’s all happening because of you!
Patients, advocates and researchers have worked tirelessly to elevate our disease at the U.S. National Institutes of Health. On October 29, Dr. Francis Collins, Director of NIH, announced promising changes to the federal research program on ME/CFS, saying “We are going to ramp this up.”

“…it means it’s moved toward the front of the stove.” Dr. Ian Lipkin, Columbia University, Center for Infection & Immunity

One important catalyst to NIH’s promising changes was publication of the Columbia University study findings this Spring. Two publications – the CFI multi-site study and Simmaron’s spinal fluid study – document groundbreaking findings of immune abnormalities. They coincided with game-changing recommendations from the prestigious Institute of Medicine and NIH Pathways to Prevention Program identifying the “urgent need” for ME/CFS research. Simmaron is a proud collaborator in multiple Columbia studies, including our signature spinal fluid studies which distinguish ME/CFS patients from those with Multiple Sclerosis. As we move the pace and quality of research up in this disease, our Columbia collaborations become even more important.

Help us continue the Columbia research. Simmaron’s priority is pursuing the next generation of spinal fluid studSR_Donate_6.9.14_1-300x150.pngies with Drs. Ian Lipkin and Mady Hornig, to generate more specific information so we can translate findings into potential diagnostics and treatments.
Phase 2 of the Columbia spinal fluid study is a 2-year project, and we are most of the way through year 1. We need to raise $32,000 to finish funding year 1, and more to fund year 2.
Additionally, given new attention at NIH, now is the time to analyze historical data from one of the field’s most experienced clinicians to catalyze more clinical trials. Simmaron has a unique ability to work with Dr. Daniel Peterson, its Scientific Advisor, to extract data from his rich clinical experience monitoring immune testing and utilizing immune-based treatments. We need your help to make it feasible.
Simmaron is proud to contribute to the rise of ME/CFS science, and we are moved by the knowledge that the more we do now, the sooner the scientific community will fully embrace our disease.
There are more details in Simmaron’s year-end newsletter here. Please remember us on #GivingTuesday, and know that every gift speeds progress.
 

Facebook
Twitter
WhatsApp
Email

1 thought on “Help Simmaron Fund the Rise of ME/CFS Research!”

  1. Patients and loved ones should know that Simmaron Research is run by Volunteers, there is no Paid President or staff…So all Donations go directly to Research…The volunteers have worked very hard to produce substantial Results….Follow the link http://simmaronresearch.com/staff-board/ to see the Voluntary Board, who depend upon other volunteer staff such as Anita P. to keep Simmaron running… My appreciation and thanks to them all.

Comments are closed.

Latest News

Blue square image with starbursts in the corners. the words, submit long covid drug recommendations to recover -tlc! are in the middle of the image, surrounded by thin white lines. the meaction logo is at the top of the image.

Submit Long COVID Drug Recommendations to RECOVER-TLC!

Last month, RECOVER TLC met at NIH headquarters in Bethesda. The goal was to initiate a drug development strategy for Long COVID clinical trials. Now, RECOVER TLC has opened the RECOVER-TLC Intervention Information Request Form, where you can make suggestions about which drugs and other interventions to trial!  Anyone can submit a therapeutic for consideration

Read More »
A classroom of people watching a panel discussion.

The RECOVER-Treating Long COVID (RECOVER TLC) The Path Forward

The RECOVER-Treating Long COVID (RECOVER TLC) Kick-off Meeting was Sept 23-25 in person and over Zoom. I had the privilege of attending over Zoom and Jaime Seltzer, #MEAction’s Scientific Director, represented the needs of the ME community in person and as an invited member of a panel on clinical trial design. There were many speakers

Read More »
Scroll to Top